A large body of evidence accumulated over the two decades of the “interferon era” shows conclusively that HCV eradication (sustained virological response, SVR) in patients with cirrhosis reduces both liver and nonliverrelated deaths.1,2 When cirrhosis is subclassified ac‐ cording to the stage of portal hypertension, it is apparent that the benefit of SVR is higher in patients without clinically...

or a number of years, immunologists have strived to Funderstand the mechanisms associated with treatment-induced eradication of hepatitis C virus (HCV). However, interferon (IFN)-a–based therapies did not allow studies examining the role of the virus itself on innate and adaptive immunity to HCV. The study by Serti et al published in this issue of Gastroenterology provides a unique opportunity ...

BACKGROUND Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy. Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper provides a review of the neuropsych...

Treatment options for chronic hepatitis C virus (HCV) infection have drastically changed since the development and licensing of new potent direct-acting antivirals (DAAs). The majority of DAAs are extensively metabolized by liver enzymes and have the ability to influence cytochrome P450 (CYP) enzymes. Additionally, these DAAs are both substrates and inhibitors of drug transporters, which makes ...

The development and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years have heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus (HBV, HCV, and HDV). The introduction of direct acting antivirals (DDAs) for the treatment of HBV carriers has permitted the long-term use of ...

Introduction. The consistent emergence/reemergence of filoviruses into a world that previously lacked an approved pharmaceutical intervention parallels experience repeatedly played-out for most other emerging pathogenic zoonotic viruses. Investment to preemptively develop effective and low-cost prophylactic therapeutic interventions against viruses have high potential emergence societal impact ...